title: Nevirapine inhibits the anti-HIV activity of CD8+ cells.
abstract: Antiretroviral therapy (ART) significantly reduced the CD8 cell noncytotoxic anti-HIV response in 12 HIV-1-infected subjects (P < 0.0001). In separate experiments, CD8(+) cells from long-term survivors were cocultured with HIV-infected CD4(+) cells using varying concentrations of anti-HIV drugs. The antiviral function of CD8(+) cells from 4 of the 14 LTSs was reduced with exposure to 10 μM of nevirapine (P < 0.05). The antiviral activity of CD8(+) cells from 2 LTSs was inhibited by 5 μM of zidovudine. These studies indicate that nevirapine and probably zidovudine can inhibit the anti-HIV activity of CD8(+) cells and thus could influence the effectiveness of antiretroviral therapy.
authors: Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143-1270, USA.
authors: Lianxing
authors: L
authors: Liu
authors: Lin
authors: L
authors: Wang
authors: Liusheng
authors: L
authors: Huang
authors: Vincent
authors: V
authors: Siu
authors: Fernando
authors: F
authors: Teque
authors: Francesca T
authors: FT
authors: Aweeka
authors: Jay A
authors: JA
authors: Levy
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*; D002478:Cells, Cultured; D018920:Coculture Techniques; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D006679:HIV Seropositivity / Q000188:drug therapy; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D019829:Nevirapine / Q000494:pharmacology; D012367:RNA, Viral / Q000097:blood; D015215:Zidovudine / Q000494:pharmacology
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D015215:Zidovudine; D019829:Nevirapine
references: Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):597-602
references: 11136234
references: Clin Exp Immunol. 1994 Jul;97(1):68-75
references: 7518369
references: AIDS. 2007 Nov 30;21(18):2483-91
references: 18025885
references: Virology. 1997 Jun 23;233(1):193-8
references: 9201229
references: Niger J Med. 2009 Jul-Sep;18(3):332-3
references: 20120657
references: South Med J. 2011 Feb;104(2):95-101
references: 21206421
references: AIDS Res Hum Retroviruses. 2006 Jul;22(7):640-7
references: 16831088
references: AIDS. 2005 Nov 18;19(17):2046-7
references: 16260917
references: Toxicology. 2012 Nov 15;301(1-3):33-9
references: 22750752
references: AIDS. 2011 Jan 28;25(3):341-4
references: 21157295
references: Clin Infect Dis. 2007 Feb 1;44(3):456-8
references: 17205459
references: Blood. 2002 Jun 1;99(11):4225-7
references: 12010831
references: J Clin Invest. 1991 Apr;87(4):1462-6
references: 1707063
references: J Virol. 1999 Jan;73(1):797-800
references: 9847391
references: J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):439-46
references: 16652051
references: AIDS. 2012 Apr 24;26(7):833-41
references: 22301417
references: Clin Pharmacokinet. 2010;49(1):17-45
references: 20000887
references: N Engl J Med. 1998 Aug 6;339(6):405-6
references: 9696654
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):259-76
references: 15833290
references: J Immunol Methods. 2005 Sep;304(1-2):137-50
references: 16129447
references: J Pharm Biomed Anal. 2003 Apr 1;31(5):953-9
references: 12684107
references: Ther Drug Monit. 2011 Jun;33(3):265-74
references: 21566505
references: Nat Med. 1999 May;5(5):518-25
references: 10229228
references: J Infect Dis. 2000 Sep;182(3):945-9
references: 10950795
references: Chem Res Toxicol. 2012 Aug 20;25(8):1708-19
references: 22793666
references: Indian J Pharmacol. 2010 Jun;42(3):189-91
references: 20871773
references: Virology. 1985 Dec;147(2):326-35
references: 2416116